Literature DB >> 24942100

Diagnosing attention-deficit hyperactivity disorder (ADHD) in children involved with child protection services: are current diagnostic guidelines acceptable for vulnerable populations?

B Klein1, G Damiani-Taraba, A Koster, J Campbell, C Scholz.   

Abstract

Children involved with child protection services (CPS) are diagnosed and treated for attention-deficit hyperactivity disorder (ADHD) at higher rates than the general population. Children with maltreatment histories are much more likely to have other factors contributing to behavioural and attentional regulation difficulties that may overlap with or mimic ADHD-like symptoms, including language and learning problems, post-traumatic stress disorder, attachment difficulties, mood disorders and anxiety disorders. A higher number of children in the child welfare system are diagnosed with ADHD and provided with psychotropic medications under a group care setting compared with family-based, foster care and kinship care settings. However, children's behavioural trajectories change over time while in care. A reassessment in the approach to ADHD-like symptoms in children exposed to confirmed (or suspected) maltreatment (e.g. neglect, abuse) is required. Diagnosis should be conducted within a multidisciplinary team and practice guidelines regarding ADHD diagnostic and management practices for children in CPS care are warranted both in the USA and in Canada. Increased education for caregivers, teachers and child welfare staff on the effects of maltreatment and often perplexing relationship with ADHD-like symptoms and co-morbid disorders is also necessary. Increased partnerships are needed to ensure the mental well-being of children with child protection involvement.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  ADHD diagnosis; child protection services; multidisciplinary practices; overmedicated

Mesh:

Substances:

Year:  2014        PMID: 24942100     DOI: 10.1111/cch.12168

Source DB:  PubMed          Journal:  Child Care Health Dev        ISSN: 0305-1862            Impact factor:   2.508


  6 in total

1.  A Multimodal Intervention for Children with ADHD Reduces Inequity in Health and Education Outcomes.

Authors:  Jennifer E Enns; Jason R Randall; Mark Smith; Dan Chateau; Carole Taylor; Marni Brownell; James M Bolton; Elaine Burland; Alan Katz; Laurence Y Katz; Nathan C Nickel
Journal:  Can J Psychiatry       Date:  2017-02-01       Impact factor: 4.356

2.  Causal modelling of variation in clinical practice and long-term outcomes of ADHD using Norwegian registry data: the ADHD controversy project.

Authors:  Arnstein Mykletun; Tarjei Widding-Havneraas; Ashmita Chaulagain; Ingvild Lyhmann; Ingvar Bjelland; Anne Halmøy; Felix Elwert; Peter Butterworth; Simen Markussen; Henrik Daae Zachrisson; Knut Rypdal
Journal:  BMJ Open       Date:  2021-01-19       Impact factor: 2.692

3.  Differentiating "Attachment Difficulties" From Autism Spectrum Disorders and Attention Deficit Hyperactivity Disorder: Qualitative Interviews With Experienced Health Care Professionals.

Authors:  Barry Coughlan; Marinus H van IJzendoorn; Matt Woolgar; Emma J L Weisblatt; Robbie Duschinsky
Journal:  Front Psychol       Date:  2022-02-07

4.  Prevalence of neurodevelopmental disorders and their impact on the health and social well-being among looked after children (LAC): a systematic review protocol.

Authors:  Nicola Heady; Alan Watkins; Ann John; Hayley Hutchings
Journal:  Syst Rev       Date:  2022-03-19

5.  ADHD Symptomatology, Executive Function and Cognitive Performance Differences between Family Foster Care and Control Group in ADHD-Diagnosed Children.

Authors:  María Peñarrubia; Ignasi Navarro-Soria; Jesús Palacios; Javier Fenollar-Cortés
Journal:  Children (Basel)       Date:  2021-05-17

6.  Children's advocacy centre fails to respond to dental, mental and physical ill-health in abused children.

Authors:  Linn Göransson; Sofia Ekermann; Christoffer Dovik; Gunilla Klingberg; Karin Ridell; Louise Laurell
Journal:  Acta Paediatr       Date:  2022-03-22       Impact factor: 4.056

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.